Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...